Clinical Trials Logo

Citation(s)

Lenvatinib Combined Pembrolizumab as a Second-line Treatment in Advanced Hepatobiliary Tumors: a Single-center, Single-arm, Non-randomized Clinical Study

Details for clinical trial NCT03895970